BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cusatuzumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cusatuzumab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06384261-3085@assetmemo.bio
DTSTAMP:20261121T005829Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Cusatuzumab: Phase 2 readout est. (NCT06384261)
DESCRIPTION:Cusatuzumab\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and A
 zacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy\nEstima
 ted primary completion: January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/cusatuzumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06384261
URL:https://assetmemo.bio/drug/cusatuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04150887-3085@assetmemo.bio
DTSTAMP:20261121T005829Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Cusatuzumab: Phase 1 readout est. (NCT04150887)
DESCRIPTION:Cusatuzumab\, phase 1\, Acute Myeloid Leukemia.\nStudy: Cusatuz
 umab in Combination With Background Therapy for the Treatment of Participa
 nts With Acute Myeloid Leukemia\nEstimated primary completion: 15 May 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cusatuzumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04150887
URL:https://assetmemo.bio/drug/cusatuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
